KUSTE BIOPHARMA, a clinical-stage biotechnology company founded in 2019 by seasoned life sciences entrepreneurs, focused on the development of compounds for inflammatory diseases, participated in the following conferences:

• BioTrinity on 26-27 April 2022 in London
  
  
• LSX World Congress 10-11 May 2022 in London
  
  
• Bio€quity Europe 16-18 may 2022 in Milan
  
  

KUSTE Biopharma is a clinical-stage biotechnology company founded by seasoned life sciences entrepreneurs. KUSTE develops molecules for severe chronic inflammatory diseases.

The company’s lead indication is Interstitial Cystitis also called Bladder Pain Syndrome (IC/BPS). Brimapitide, a small penetrating peptide, JNK inhibitor, demonstrated to be safe and effective in large patient pool, has been developed for IC/BPS in a Phase 2a. KUSTE is now launching Phase 2b. Among other indications we are developing Ulcerative Colitis now in Pre-clinical, preparing for Phase 1/2a.

For more information : www.kustebiopharma.com

PRESS CONTACT
Bénédicte Freyler
benedicte.freyler@kustebiopharma.com